Groupama Asset Managment Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Groupama Asset Managment acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 404,000 shares of the biotechnology company's stock, valued at approximately $60,000. Groupama Asset Managment owned about 0.67% of Ascendis Pharma A/S as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ASND. Nomura Asset Management Co. Ltd. raised its position in Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock worth $2,688,000 after purchasing an additional 5,371 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $886,000. Main Management ETF Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S in the third quarter worth approximately $927,000. XTX Topco Ltd bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $1,692,000. Finally, Zimmer Partners LP purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at $11,646,000.

Analyst Ratings Changes

Several research firms have recently weighed in on ASND. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. TD Cowen lowered their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th. Finally, Stifel Nicolaus raised their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Trading Down 2.1 %

Shares of ASND stock traded down $2.75 during trading hours on Tuesday, reaching $129.67. 306,478 shares of the company's stock were exchanged, compared to its average volume of 449,891. The company has a market cap of $7.86 billion, a price-to-earnings ratio of -16.05 and a beta of 0.67. Ascendis Pharma A/S has a fifty-two week low of $101.43 and a fifty-two week high of $161.00. The stock's 50 day moving average is $129.86 and its 200-day moving average is $132.69.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.